Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 4 | 2021 | 565 | 0.730 |
Why?
|
| Laboratories | 1 | 2021 | 46 | 0.680 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 537 | 0.670 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 893 | 0.670 |
Why?
|
| Gene Deletion | 3 | 2021 | 352 | 0.590 |
Why?
|
| Genomics | 4 | 2022 | 848 | 0.540 |
Why?
|
| Uniparental Disomy | 2 | 2020 | 5 | 0.450 |
Why?
|
| Trisomy | 2 | 2017 | 53 | 0.430 |
Why?
|
| Chromosome Aberrations | 3 | 2023 | 350 | 0.420 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2013 | 12 | 0.400 |
Why?
|
| Mutation | 7 | 2024 | 4272 | 0.400 |
Why?
|
| ABO Blood-Group System | 1 | 2013 | 59 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 2465 | 0.350 |
Why?
|
| Chromosome Disorders | 1 | 2011 | 98 | 0.350 |
Why?
|
| Neural Tube Defects | 2 | 2008 | 41 | 0.340 |
Why?
|
| Gene Duplication | 1 | 2011 | 128 | 0.330 |
Why?
|
| Myeloproliferative Disorders | 2 | 2024 | 146 | 0.330 |
Why?
|
| Neoplasms | 2 | 2022 | 3169 | 0.300 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 691 | 0.300 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2007 | 2 | 0.260 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 478 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 46 | 0.250 |
Why?
|
| Clonal Evolution | 2 | 2024 | 17 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 826 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 2484 | 0.240 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2005 | 47 | 0.230 |
Why?
|
| Pedigree | 5 | 2019 | 961 | 0.230 |
Why?
|
| Meningomyelocele | 1 | 2005 | 25 | 0.230 |
Why?
|
| Meningocele | 1 | 2005 | 6 | 0.230 |
Why?
|
| Oxidoreductases | 1 | 2005 | 111 | 0.230 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 16 | 0.230 |
Why?
|
| Blast Crisis | 1 | 2024 | 37 | 0.220 |
Why?
|
| Introns | 1 | 2005 | 300 | 0.210 |
Why?
|
| Receptors, Cholinergic | 1 | 2024 | 75 | 0.210 |
Why?
|
| Cerebellar Vermis | 1 | 2023 | 5 | 0.200 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2023 | 20 | 0.200 |
Why?
|
| Alleles | 2 | 2006 | 1139 | 0.190 |
Why?
|
| Microcephaly | 1 | 2023 | 78 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 156 | 0.190 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2023 | 66 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2023 | 35 | 0.190 |
Why?
|
| Calpain | 1 | 2023 | 113 | 0.190 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 826 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 147 | 0.180 |
Why?
|
| INDEL Mutation | 1 | 2021 | 33 | 0.170 |
Why?
|
| Epileptic Syndromes | 1 | 2021 | 8 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 64 | 0.170 |
Why?
|
| Spasms, Infantile | 1 | 2021 | 39 | 0.170 |
Why?
|
| Polycythemia Vera | 1 | 2020 | 22 | 0.170 |
Why?
|
| Humans | 24 | 2024 | 93515 | 0.170 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 59 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 192 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2022 | 1660 | 0.160 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2019 | 4 | 0.160 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 9 | 0.160 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2019 | 11 | 0.160 |
Why?
|
| Genetics, Medical | 1 | 2020 | 51 | 0.150 |
Why?
|
| Granular Cell Tumor | 1 | 2019 | 5 | 0.150 |
Why?
|
| Exome | 1 | 2020 | 141 | 0.150 |
Why?
|
| Male | 15 | 2024 | 44557 | 0.150 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 11 | 0.140 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 701 | 0.140 |
Why?
|
| Mosaicism | 2 | 2021 | 73 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 319 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 300 | 0.140 |
Why?
|
| Composite Lymphoma | 1 | 2017 | 2 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2017 | 33 | 0.130 |
Why?
|
| Lymphoma, Follicular | 1 | 2017 | 73 | 0.130 |
Why?
|
| T-Box Domain Proteins | 1 | 2018 | 127 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2024 | 2479 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 107 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2008 | 543 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 204 | 0.120 |
Why?
|
| Pregnancy | 3 | 2018 | 3147 | 0.120 |
Why?
|
| Female | 12 | 2024 | 48702 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 38 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2013 | 80 | 0.100 |
Why?
|
| Phenotype | 3 | 2023 | 2544 | 0.090 |
Why?
|
| Ichthyosis, X-Linked | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cytogenetic Analysis | 1 | 2011 | 71 | 0.090 |
Why?
|
| Hair | 1 | 2011 | 55 | 0.090 |
Why?
|
| Malformations of Cortical Development | 1 | 2011 | 45 | 0.090 |
Why?
|
| Syndrome | 1 | 2011 | 437 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2544 | 0.080 |
Why?
|
| Muscle Weakness | 2 | 2008 | 67 | 0.080 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2008 | 11 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 63 | 0.070 |
Why?
|
| Indians, North American | 1 | 2008 | 48 | 0.070 |
Why?
|
| Twins | 1 | 2008 | 64 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2018 | 665 | 0.070 |
Why?
|
| Mothers | 1 | 2008 | 142 | 0.070 |
Why?
|
| Haplotypes | 2 | 2008 | 647 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2365 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 268 | 0.060 |
Why?
|
| Family | 1 | 2008 | 324 | 0.060 |
Why?
|
| Folic Acid | 1 | 2006 | 62 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2007 | 211 | 0.060 |
Why?
|
| Exons | 2 | 2020 | 450 | 0.060 |
Why?
|
| Vitamin A | 1 | 2005 | 27 | 0.060 |
Why?
|
| Organogenesis | 1 | 2005 | 50 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1105 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2007 | 700 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 12269 | 0.050 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2024 | 36 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 146 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 20434 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2005 | 241 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 474 | 0.050 |
Why?
|
| Protein Domains | 1 | 2024 | 161 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2023 | 51 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2023 | 106 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2023 | 101 | 0.050 |
Why?
|
| Genotype | 1 | 2007 | 1866 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 7061 | 0.040 |
Why?
|
| Cerebellum | 1 | 2023 | 248 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 630 | 0.040 |
Why?
|
| Adult | 4 | 2024 | 27918 | 0.040 |
Why?
|
| Sequence Inversion | 1 | 2021 | 3 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 379 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 2020 | 32 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 25 | 0.040 |
Why?
|
| Facies | 1 | 2019 | 29 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2021 | 3829 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 49 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 64 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 295 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 28155 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 27573 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2020 | 219 | 0.040 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2018 | 7 | 0.040 |
Why?
|
| Craniofacial Abnormalities | 1 | 2018 | 35 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 273 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 321 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1917 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 297 | 0.030 |
Why?
|
| Tetrasomy | 1 | 2017 | 3 | 0.030 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2018 | 52 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2017 | 33 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2018 | 69 | 0.030 |
Why?
|
| Risk Factors | 1 | 2008 | 5899 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 456 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2017 | 40 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 960 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2017 | 140 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2019 | 217 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 361 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 203 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 2012 | 0.030 |
Why?
|
| Zebrafish | 1 | 2018 | 339 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 367 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 630 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1799 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 3911 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 6930 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2011 | 12 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2014 | 506 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2495 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 578 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 10164 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1922 | 0.020 |
Why?
|
| Malignant Hyperthermia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Contracture | 1 | 2008 | 18 | 0.020 |
Why?
|
| North Carolina | 1 | 2008 | 56 | 0.020 |
Why?
|
| Consanguinity | 1 | 2008 | 72 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 84 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 207 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2715 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 531 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7622 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7355 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 9099 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1953 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2006 | 131 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 9606 | 0.010 |
Why?
|